NVX-CoV2373 (Novavax) NVX-CoV2373 (Novavax) is produced by employing nanoparticle technology. In this technology, complete genetic sequence of SARS-CoV-2 is used to generate full-length perfusion spike (S) protein which is combined with Matrix-M. Clinical trials are being conducted to conclude the efficacy and side-effects of this vaccine. Recent trials show efficient binding with human receptors. NVX-CoV2373 (Novavax) is administered as 2-dose series with difference of 21 days in between.